Key facts
- This page summarizes Maulik Nanavaty's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2022, 15:28.
Maulik Nanavaty - 28 Feb 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)
- Reporting relationship
- SVP & Pres, Neuromodulation
- Issuer ticker
- BSX
- Reported as of
- 28 Feb 2022
- Net transaction value
- -$24,912
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2022, 15:28:54 UTC
- Prior SEC filing
- 24 Feb 2022
- Next SEC filing
- 27 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan Thompson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Maulik Nanavaty filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 02 Mar 2022.
Change
- Previous filing in this sequence was filed on 24 Feb 2022.
- Current net transaction value: -$24,912.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BSX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,630
- Change %
- +0.93%
- Price
- $0.000000
- Shares after
- 177,822
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
BSX
transaction
Common Stock
Tax liability
- Transaction value
- $24,912
- Shares
- -564
- Change %
- -0.32%
- Price
- $44.17
- Shares after
- 177,258
- Date
- 28 Feb 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BSX
transaction
Derivative
Deferred Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,630
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,630
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Footnote F2
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.